{
  "extraction_metadata": {
    "timestamp": "2025-10-01T13:21:17.946286",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "temperature": 0.1
  },
  "outcomes_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "Outcomes": "all-cause mortality, overall survival (OS), time to progression (TTP), time to symptomatic progression (TTSP), tumor response rate, overall response rate (ORR), disease control rate (DCR), tumor reduction, mRECIST response, recurrence-free survival, disease recurrence, local control, length of hospital stay, days of missed work, adverse events, hand-foot syndrome, diarrhoea, hypertension, skin rash, desquamation, rash, liver failure, post-treatment complications, pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), fatigue (EORTC QLQ-HCC18), cognitive functioning (EORTC QLQ-C30), health status (EQ-5D visual analogue scale), global health status (EORTC QLQ-C30), function scales (EORTC QLQ-C30), function scales (EORTC QLQ-HCC18), symptoms (EORTC QLQ-C30 symptom scales), symptoms (EORTC QLQ-HCC18 symptom scales), time to deterioration (score increase by at least 10 points over baseline; EORTC QLQ-C30 and EORTC QLQ-HCC18), quality of life, health-related quality of life, European Quality of Life – 5 Dimensions Visual Analogue Scale (EQ-5D VAS)",
      "ChunksUsed": 25,
      "ContextTokens": 5410
    },
    "CZ": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "CZ",
      "Outcomes": "",
      "ChunksUsed": 1,
      "ContextTokens": 202
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "Outcomes": "all-cause mortality, overall survival (OS), time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), tumor response rate, overall response rate (ORR), tumor reduction, recurrence-free survival, disease progression, local control, length of hospital stay, days of missed work, adverse events, hand-foot syndrome, diarrhoea, diarrhea, fatigue, rash, hypertension, skin rash, desquamation, hypody, liver failure, post-treatment complications, pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), cognitive functioning (health-related quality of life), liver function, quality of life, health status, EORTC QLQ-C30, EORTC QLQ-HCC18, European Quality of Life – 5 Dimensions Visual Analogue Scale (EQ-5D VAS), global health status (EORTC QLQ-C30), function scales (EORTC QLQ-C30), function scales (EORTC QLQ-HCC18), time to deterioration (EORTC QLQ-C30; defined as a score increase by at least 10 points over baseline), time to deterioration (EORTC QLQ-HCC18; defined as a score increase by at least 10 points over baseline), complications",
      "ChunksUsed": 25,
      "ContextTokens": 5475
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), progression-free survival (PFS; RECIST 1.1), time to progression (TTP), objective response rate (ORR), complete response (CR), partial response (PR), time to response, duration of response (DoR), disease control rate (DCR; mRECIST), clinical benefit rate (CBR), plasma pharmacokinetics parameters, pharmacokinetic/pharmacodynamic relationship, adverse events (general), serious adverse events, adverse events leading to discontinuation, diarrhoea, nutrition (EORTC QLQ-HCC18), pain (EORTC QLQ-C30), body image (EORTC QLQ-HCC18), role functioning (EORTC QLQ-C30), health-related quality of life (HRQoL), EORTC QLQ-C30, EORTC QLQ-HCC18, EQ-5D, EQ-5D visual analogue scale (VAS), EQ-5D health utility index (HUI), time to clinically meaningful deterioration (EORTC QLQ-C30), time to clinically meaningful deterioration (EORTC QLQ-HCC18), time to clinically meaningful deterioration (EQ-5D), cost-effectiveness, quality-adjusted life years (QALYs)",
      "ChunksUsed": 25,
      "ContextTokens": 5400
    },
    "EN": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EN",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), time to radiological disease progression, time to symptomatic disease progression (FHSI-8 questionnaire), duration of treatment, treatment discontinuation, diarrhoea, hand-foot skin reaction, dermatological toxicities, hypertension, haemorrhage, cardiac ischaemia, cardiac infarction, gastrointestinal perforation, hepatic impairment, wound healing complications, adverse events (general), health-related quality of life, quality-adjusted life years (QALYs), cost-effectiveness (incremental cost-effectiveness ratio, ICER), resource use",
      "ChunksUsed": 25,
      "ContextTokens": 4633
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 or death from any cause), objective response rate (ORR; percentage of patients with partial or complete response; RECIST 1.1), objective response rate (percentage of patients with partial or complete response; mRECIST), duration of response (time from partial or complete response to disease progression or exit), deterioration in patient quality of life (EORTC QLQ-C30), deterioration in patient quality of life (EORTC QLQ-HCC18), time to patient-reported impairment of quality of life (EORTC QLQ-C30), time to patient-reported impairment of quality of life (EORTC QLQ-C30 functional role subscale), time to patient-reported impairment of quality of life (EORTC QLQ-C30 fitness subscale), adverse events (general), serious adverse events, grade 3-4 adverse events, grade 5 adverse events, gastrointestinal disorders, bleeding, infections, liver disorders, hypothyroidism, infusion reactions, hyperthyroidism, hypertension, proteinuria, diabetes mellitus, increased aspartate aminotransferase, pruritus, diarrhoea, fever, loss of appetite, increased alanine aminotransferase, constipation, increased serum bilirubin, abdominal pain, nausea, cough, thrombocytopenia, weight loss, epilepsy, palmar rash, asthenia, hyporexia, neutropenia, hand-foot syndrome, arterial hypertension, need for use of medical resources, drug withdrawal due to adverse events, dose modification due to adverse events",
      "ChunksUsed": 25,
      "ContextTokens": 6817
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), progression-free survival (RECIST 1.1), time to progression, objective response rate (ORR), disease control rate, clinical benefit rate, quality of life (EQ-5D-3L), EORTC QLQ-C30, EORTC QLQ-HCC18, hypertension, diarrhoea, decreased appetite, weight loss, fatigue, hand-foot syndrome, proteinuria, dysphonia, alopecia, hepatic encephalopathy, hepatic insufficiency, ascites, abdominal pain, tumour progression, brain haemorrhage, sepsis, brain/gastrointestinal bleeding, intestinal failure, respiratory failure, cerebral vascular accident, cardiovascular arrest, myocardial infarction, haemorrhage, sudden death, arterial thromboembolic events, haemorrhagic events, hypothyroidism, renal adverse events, adverse events (general), serious adverse events, grade 3 adverse reactions, treatment-related deaths, discontinuation due to adverse events",
      "ChunksUsed": 25,
      "ContextTokens": 6450
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "Outcomes": "overall survival, time to symptom progression, time to progression, disease control, partial response, minor response (reduction of tumour size by 25 to 50%), stable disease (for at least 16 weeks), fatigue, bleeding, abdominal pain, hypertension (grade 3/4), diarrhoea (grade 3/4), lymphoedema (grade 3/4), hand feeding reactions (grade 3/4), adverse reactions (general), cost-effectiveness analysis",
      "ChunksUsed": 25,
      "ContextTokens": 4036
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), complete response (CR), partial response (PR), stable disease (SD), disease control rate (DCR), FACT-G (Functional Assessment of Cancer Therapy – General), EQ-5D (Euro QoL – 5 dimensions), EQ VAS (Euro QoL visual analogue scale), number needed to harm (NNH), number needed to treat (NNT), hazard ratio (HR), mean difference (MD), relative risk (RR), risk difference (RD), infections, lymphopenia, anorexia, hypophosphataemia, haemorrhage, hypertension, diarrhoea, nausea, vomiting, constipation, dry skin, rash, alopecia, hand-foot skin reaction, erythema, pruritus, arthralgia, fatigue, pain, fever, decreased weight, increased amylase, increased lipase, folliculitis, leukopenia, neutropenia, anaemia, thrombocytopenia, hypothyroidism, hypocalcaemia, hypokalaemia, hyponatraemia, hypoglycaemia, depression, peripheral sensory neuropathy, dysgeusia, tinnitus, congestive heart failure, myocardial ischaemia, myocardial infarction, flushing, rhinorrhoea, dysphonia, stomatitis, dyspepsia, dysphagia, gastro oesophageal reflux disease, keratoacanthoma, squamous cell cancer of the skin, dermatitis exfoliative, acne, skin desquamation, hyperkeratosis, myalgia, muscle spasms, renal failure, proteinuria, erectile dysfunction, asthenia, influenza like illness, mucosal inflammation, transient increase in transaminases, secondary cancer, dyspnoea, pleural effusion, cough, back pain, limb pain, deaths, treatment-emergent adverse events (TEAEs), economic outcomes (quality-adjusted life years, QALYs), cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
      "ChunksUsed": 25,
      "ContextTokens": 5663
    },
    "PT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PT",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), progression-free survival (modified RECIST criteria), time to progression (TTP), objective response rate (ORR), quality of life, EORTC QLQ-C30, EORTC QLQ-HCC18, pharmacokinetic parameters, vital signs, laboratory haematological testing, laboratory biochemical testing, urinalysis, electrocardiography, adverse events, adverse events (graded by National Cancer Institute), grade 3 adverse reactions, grade 4 adverse reactions, treatment-related mortality, dropout rate for toxicity, tumour haemorrhage, ischaemic stroke, respiratory failure, sudden death",
      "ChunksUsed": 22,
      "ContextTokens": 3419
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "Outcomes": "overall survival (OS; time from randomization to death from any cause), progression-free survival (PFS), objective tumour response, time to tumour progression, adverse reactions leading to discontinuation of treatment, quality of life weights (EQ-5D-3L-converted weights with Dolan tariff), state-specific quality of life weights, cost per quality-adjusted life year (QALY), cost-benefit analysis, Eastern Cooperative Oncology Group Performance Status (ECOG PS), Child-Pugh scale, adverse reactions of grade 3 or higher, adverse events (general)",
      "ChunksUsed": 25,
      "ContextTokens": 4541
    }
  }
}